BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has confirmed that it would be getting statistical analysis of results from study that shows universal flu vaccine (M-001) of the firm, which was provided in BVX-005 phase II trial that had taken place three years back. This gave participants gave participants with increased immunogenicity against future strains that were not there at the time of the study- in particular the current newly emerged H3N2 influenza strain that caused the epidemic in the United States in 2015.

Three years back, about 120 elderly participants took part in BVX-005 trial. The trial was done well showing induction of both humoral as well as cellular immune responses to BiondVax's vaccine.

In the trial, almost 85 percent were tested with M-001 universal flu vaccine some weeks before the o immunization with TIV. But, the firm has confirmed that the BiondVax exposed blood plasma samples from BVX-005 participants to current influenza flu epidemic H3N2 strain that did not exist in 2012

BiondVaxassessed HAI antibodies in every blood plasma sample and found out quite a big level of protective antibodies against H3N2 strain in samples taken from participants getting M-001 vaccine vis-à-vis control group.

An average of 50% or greater of participants in experimental group getting M-001 showed immunogenicity against the new strain.  

Ron Babecoff, BiondVax's President and CEO, opined that the firm is glad that participants getting vaccine in trial three years ago have higher immunogenicity. He added that independently provided statistical analysis are essential because M-001 gives safety net by broadening the immunogenicity to existing as well as future flu strains.

The CEO added that is the vaccine is approved by regulatory bodies as well as available in the market during last winter.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites